Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.
about
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesSPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.Asthma and risk of myelodysplastic syndromes: a population-based cohort study.Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A.Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities.
P2860
Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy and safety of lenalid ...... e with chromosome 5q deletion.
@ast
Efficacy and safety of lenalid ...... e with chromosome 5q deletion.
@en
type
label
Efficacy and safety of lenalid ...... e with chromosome 5q deletion.
@ast
Efficacy and safety of lenalid ...... e with chromosome 5q deletion.
@en
prefLabel
Efficacy and safety of lenalid ...... e with chromosome 5q deletion.
@ast
Efficacy and safety of lenalid ...... e with chromosome 5q deletion.
@en
P2860
P356
P1476
Efficacy and safety of lenalid ...... me with chromosome 5q deletion
@en
P2093
Rami S Komrokji
Vu H Duong
P2860
P304
P356
10.1177/2040620711435659
P50
P577
2012-04-01T00:00:00Z